NAMSNewAmsterdam Pharma Company N.V.
$21.58-19% 1Y
$21.58
$21.1452 weeks$41.45
Is the price fair?
What NAMS's price assumes
NewAmsterdam Pharma Company N.V. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 550× revenue.
550
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.20
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 6.20
- EV / EBIToperating margin −3432%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $3.71B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.